Legend Biotech (LEGN)

• Market cap: $6.02B
• 1 day: -1.97%
• 5 days: 4.09%
• 1 month: -13.55%
• 3 months: 0.43%
• 6 months: -23.88%
• Year to date: -5.56%
• 1 year: -32.83%
• 5 years: -11.35%
• 10 years: -11.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Employees: 2,609

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 52

33% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 8 (+2) [Q4]

1.89% more ownership

Funds ownership: 25.04% [Q3] → 26.93% (+1.89%) [Q4]

9% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 35

1% more funds holding

Funds holding: 205 [Q3] → 207 (+2) [Q4]

27% less capital invested

Capital invested by funds: $4.44B [Q3] → $3.23B (-$1.21B) [Q4]

43% less call options, than puts

Call options by funds: $8.76M | Put options by funds: $15.3M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $75 129% upside
• Avg. target: $78 136% upside
• High target: $80 144% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 57 / 186 met price target	129% upside $75	Buy Reiterated	16 Apr 2025
Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target	144% upside $80	Overweight Maintained	17 Mar 2025